Clinical trials
Chronic Hepatitis B Infection clinical trials
Below are recruiting chronic hepatitis b infection clinical trials, each written for real people, not researchers. We’re tracking 161 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06696664Recruiting
Genetic study of chronic hepatitis B cure with long-acting interferon
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
Beijing, Beijing MunicipalityAges 18–70 - NCT07573943RecruitingPhase 4
ASC22 with peginterferon to cure chronic hepatitis B
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT06803368Recruiting
Recovery and maintenance strategies for chronic hepatitis B
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
Beijing, Beijing MunicipalityAges 18–65 - NCT06853886Recruiting
Genetic study for hepatitis B patients to find new treatment pathways
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
LimogesAges 18 years+ - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT06885710RecruitingPhase 1
T cell therapy with antivirals for chronic hepatitis B
This study tests a new treatment that uses your own immune cells (T cells) modified to attack the hepatitis B virus, combined with standard antiviral medication. It is for people with chronic hepatitis B who have a specific HLA type and no advanced liver scarring.
ShanghaiAges 18–65 - NCT06906016Recruiting
New blood tests for hepatitis B
This study looks at new blood tests (biomarkers) to better understand chronic hepatitis B and how it affects treatment decisions. It may help doctors find better ways to manage your condition.
Créteil, CréteilAges 18 years+ - NCT06963710RecruitingPhase 2
New Hepatitis B Treatment vs Standard Drug
This trial tests a new oral medication (ALG-000184) compared to an existing drug (tenofovir) for people with chronic hepatitis B who have not been treated recently. It aims to see if the new drug is better at lowering the virus and improving liver health.
Chandler, ArizonaAges 18–65 - NCT06966908Recruiting
Managing hepatitis B in non-specialty hospital settings
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
Guangzhou, GuangdongAges Any age - NCT07059403RecruitingPhase 1
Safety and dose study of a new hepatitis B vaccine in healthy adults
This study is testing a new hepatitis B vaccine called SN2001 in healthy adults. It will check how safe the vaccine is, what dose works best, and how well it helps your body build protection against hepatitis B.
Herston, QueenslandAges 18–55 - NCT07079150Recruiting
Long-term pegylated interferon study for HBV families with poor outcomes
This study looks at how well pegylated interferon alpha-2b works over the long term for people with chronic hepatitis B who come from families where the virus has caused serious liver problems like cirrhosis or liver cancer. The goal is to see if this treatment can help prevent these bad outcomes in family members.
Xi'an, ShaanxiAges 18–70 - NCT07090759RecruitingPhase 3
Test of new drug for hepatitis B not fully controlled by current treatment
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
Hangzhou, ZhejiangAges 18–70 - NCT07137247Recruiting
How the immune system changes over time in chronic hepatitis B
This study tracks how the immune system works in people with chronic hepatitis B who haven't taken antiviral medication in the last 6 months. It aims to understand the natural history of the infection without treatment.
Guangzhou, GuangdongAges 1–80 - NCT07169656Recruiting
Study on reducing liver cancer risk in hepatitis B patients
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
AnyangAges 18 years+ - NCT07240350Recruiting
Hepatitis B immune response in surgery patients
This study looks at how the body's immune system responds in people with chronic hepatitis B who also need surgery on certain organs. The goal is to learn more about the immune reaction in tonsils, lymph nodes, or other tissues to help find better treatments for hepatitis B.
Guangzhou, GuangdongAges 18–75 - NCT07389044RecruitingPhase 1
Safety study of IB-001 injection in healthy people and hepatitis B patients
This study tests a new injection called IB-001 in two groups: healthy people and people with chronic hepatitis B. The goal is to see if it's safe and how the body handles it at different doses. It might offer a new treatment option for hepatitis B in the future.
ChisinauAges 18–70 - NCT07307586RecruitingPhase 3
Azvudine for new hepatitis B patients
This study tests a new pill (azvudine) to see if it can cure chronic hepatitis B in people who have never been treated before. It is for those with active infection and elevated liver enzymes.
Zhengzhou, HenanAges 18–65 - NCT07342881RecruitingPhase 1
Single dose study of pevifoscorvir in people with kidney impairment
This study tests how a single dose of the study drug, pevifoscorvir, is processed in people with different levels of kidney function. It helps understand if the dose needs to be adjusted for people with kidney problems.
Orlando, FloridaAges 18–75 - NCT07051187RecruitingPhase 1
WGc0201 for chronic hepatitis B
This trial tests a new drug called WGc0201 in adults with chronic hepatitis B who have controlled their virus with standard antiviral pills. It aims to see if WGc0201 can further reduce hepatitis B surface antigen (HBsAg) levels.
Chengdu, SichuanAges 18–65 - NCT02883647Recruiting
Stopping antiviral treatment in chronic hepatitis B
This trial studies what happens after stopping long-term hepatitis B antiviral medicine in people whose virus has stayed controlled. It also follows patients over time to see how well they remain stable and safe after stopping.
Guangzhou, GuangdongAges 18–65 - NCT07491848Recruiting
Mouth health study for hepatitis B and D patients
This study looks at mouth health in people with hepatitis B and D, including those taking a medicine called bulevirtide and those not taking it. It may help understand how these infections affect the mouth and gums.
CraiovaAges 18 years+ - NCT07519330RecruitingPhase 2
Testing HH-006 treatment for chronic hepatitis B
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Chongqing, Chongqing MunicipalityAges 18–45 - NCT07610772RecruitingPhase 1
Safety study of a new hepatitis B antibody for hepatitis D
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
AarhusAges 18–70 - NCT07298577Enrolling by invitation
Using blood test and ultrasound to find early liver cancer in Asia
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Bangkok Noi, BangkokAges 18 years+
Hear when a new Chronic Hepatitis B Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis b infection?
- Yes. Clin2 currently lists 161 recruiting chronic hepatitis b infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis b infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis b infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.